AP2006003701A0 - 1H-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors - Google Patents

1H-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors

Info

Publication number
AP2006003701A0
AP2006003701A0 AP2006003701A AP2006003701A AP2006003701A0 AP 2006003701 A0 AP2006003701 A0 AP 2006003701A0 AP 2006003701 A AP2006003701 A AP 2006003701A AP 2006003701 A AP2006003701 A AP 2006003701A AP 2006003701 A0 AP2006003701 A0 AP 2006003701A0
Authority
AP
ARIPO
Prior art keywords
thieno
kinase inhibitors
pyrazole derivatives
derivatives useful
pyrazole
Prior art date
Application number
AP2006003701A
Other languages
English (en)
Inventor
Paola Vianello
Sergio Vioglio
Simona Bindi
Daniele Fancelli
Dania Tesei
Mario Varasi
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Publication of AP2006003701A0 publication Critical patent/AP2006003701A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2006003701A 2004-02-03 2005-02-02 1H-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors AP2006003701A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54145204P 2004-02-03 2004-02-03
PCT/EP2005/001021 WO2005074922A1 (en) 2004-02-03 2005-02-02 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
AP2006003701A0 true AP2006003701A0 (en) 2006-08-31

Family

ID=34837492

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003701A AP2006003701A0 (en) 2004-02-03 2005-02-02 1H-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors

Country Status (37)

Country Link
US (2) US8138217B2 (es)
EP (1) EP1711177B1 (es)
JP (1) JP4908233B2 (es)
KR (1) KR20060124734A (es)
CN (1) CN1946395B (es)
AP (1) AP2006003701A0 (es)
AR (1) AR047531A1 (es)
AT (1) ATE396724T1 (es)
AU (1) AU2005210114B2 (es)
BR (1) BRPI0507375A (es)
CA (1) CA2555262C (es)
CR (1) CR8546A (es)
CY (1) CY1108246T1 (es)
DE (1) DE602005007181D1 (es)
DK (1) DK1711177T3 (es)
DO (1) DOP2005000014A (es)
EA (1) EA011032B1 (es)
EC (1) ECSP066767A (es)
ES (1) ES2307144T3 (es)
GE (1) GEP20094633B (es)
GT (1) GT200500020A (es)
IL (1) IL177141A0 (es)
MA (1) MA28429B1 (es)
MX (1) MXPA06008787A (es)
NO (1) NO20063768L (es)
NZ (1) NZ548896A (es)
PA (1) PA8622801A1 (es)
PE (1) PE20051095A1 (es)
PL (1) PL1711177T3 (es)
PT (1) PT1711177E (es)
SI (1) SI1711177T1 (es)
TN (1) TNSN06244A1 (es)
TW (1) TW200526204A (es)
UA (1) UA86223C2 (es)
UY (1) UY28738A1 (es)
WO (1) WO2005074922A1 (es)
ZA (1) ZA200606179B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000946A (es) * 2002-07-25 2005-05-16 Pharmacia Italia Spa Derivados heterociclicos condensados de pirazol como inhibidores de cinasa.
EP1904503B1 (en) * 2005-07-19 2013-11-06 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]-pyrazole compounds useful as kinase inhibitors
AU2006298563A1 (en) * 2005-10-06 2007-04-12 Merck & Co., Inc. Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as D-amino acid oxidase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009534307A (ja) * 2006-03-30 2009-09-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 特定の耐性腫瘍の治療のためのキナーゼ阻害剤の使用
US8119641B2 (en) 2006-05-31 2012-02-21 Nerviano Medical Sciences S.R.L. 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors
FR2904626B1 (fr) * 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
KR100923540B1 (ko) 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
CL2009001158A1 (es) * 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
ES2660892T3 (es) * 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
ES2929759T3 (es) * 2012-04-05 2022-12-01 Nerviano Medical Sciences Srl Nuevos agentes alquilantes
EP3663299B1 (en) * 2017-08-01 2023-03-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound acting as ror gamma inhibitor
US11492357B2 (en) * 2017-11-30 2022-11-08 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2015566B3 (es) 1986-02-19 1990-09-01 Duphar Int Res B V Nuevos compuestos tio que tienen actividad fungicida.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
WO2001012189A1 (en) 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
JP4555547B2 (ja) * 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
AU2002215053A1 (en) 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
CA2434066A1 (en) 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
CZ2004359A3 (cs) 2001-09-26 2004-09-15 Pharmacia Italia S.P.A. Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty
JP4751063B2 (ja) * 2002-05-17 2011-08-17 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物
DE60320560T2 (de) * 2002-07-17 2008-12-11 Pfizer Italia S.R.L. Heterobicyclische pyrazolderivate als kinaseinhibitoren
MXPA05000946A (es) * 2002-07-25 2005-05-16 Pharmacia Italia Spa Derivados heterociclicos condensados de pirazol como inhibidores de cinasa.
US20050026984A1 (en) * 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products

Also Published As

Publication number Publication date
CN1946395B (zh) 2014-04-02
JP2007520513A (ja) 2007-07-26
PA8622801A1 (es) 2005-11-25
GEP20094633B (en) 2009-03-10
EA011032B1 (ru) 2008-12-30
MA28429B1 (fr) 2007-02-01
EA200601418A1 (ru) 2006-12-29
IL177141A0 (en) 2006-12-10
NO20063768L (no) 2006-11-02
ECSP066767A (es) 2006-11-24
KR20060124734A (ko) 2006-12-05
MXPA06008787A (es) 2007-01-19
HK1101343A1 (en) 2007-10-18
ES2307144T3 (es) 2008-11-16
TNSN06244A1 (fr) 2007-12-03
TW200526204A (en) 2005-08-16
CA2555262A1 (en) 2005-08-18
ATE396724T1 (de) 2008-06-15
ZA200606179B (en) 2008-02-27
UY28738A1 (es) 2005-09-30
JP4908233B2 (ja) 2012-04-04
AU2005210114B2 (en) 2011-07-14
CA2555262C (en) 2014-10-14
GT200500020A (es) 2005-09-06
EP1711177B1 (en) 2008-05-28
PL1711177T3 (pl) 2008-11-28
BRPI0507375A (pt) 2007-07-10
DK1711177T3 (da) 2008-09-29
CN1946395A (zh) 2007-04-11
CY1108246T1 (el) 2014-02-12
AR047531A1 (es) 2006-01-25
PE20051095A1 (es) 2005-12-31
WO2005074922A1 (en) 2005-08-18
AU2005210114A1 (en) 2005-08-18
US8138217B2 (en) 2012-03-20
EP1711177A1 (en) 2006-10-18
CR8546A (es) 2007-05-30
UA86223C2 (uk) 2009-04-10
PT1711177E (pt) 2008-09-04
US8481584B2 (en) 2013-07-09
DE602005007181D1 (de) 2008-07-10
SI1711177T1 (sl) 2008-10-31
NZ548896A (en) 2010-05-28
US20050187209A1 (en) 2005-08-25
DOP2005000014A (es) 2006-08-15
US20120165311A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
HRP20180578T1 (hr) Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
TWI349672B (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ZA201202026B (en) PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
IS2843B (is) Pýrróló[3,4-c] pýrasólafleiður virkar sem kínasahindrar
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL173139A0 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
AU2003254337A1 (en) Heterobicyclic pyrazole derivatives as kinase inhibitors
IL177141A0 (en) 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS
AU2003250040A1 (en) Condensed heterocyclic pyrazole derivatives as kinase inhibitors
HK1095828A (en) Thieno[3,2-b]pyridine-6-carbonitriles as protein kinase inhibitors
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS
HK1086560A (en) Thienopyridone derivatives as kinase inhibitors
AU2002339506A1 (en) Heterocycle-carboxamide derivatives as raf kinase inhibitors
HK1090052A (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2002307861A1 (en) Imidazole-2-carboxamide derivatives as raf kinase inhibitors
HK1057745A (en) Imidazole derivatives as raf kinase inhibitors
HK1108880A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors
AU2002327758A1 (en) 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors